[{"id":"70b0b9ad-4c48-4eb5-9e7f-d4a0163de080","acronym":"K19017-004","url":"https://clinicaltrials.gov/study/NCT05684731","created_at":"2023-01-13T14:59:15.392Z","updated_at":"2024-07-02T16:35:57.631Z","phase":"Phase 1","brief_title":"Safety and Efficacy of KM1 in Subjects With Recurrent or Refractory Ovarian Cancer","source_id_and_acronym":"NCT05684731 - K19017-004","lead_sponsor":"Tongji Hospital","biomarkers":" MUC16","pipe":"","alterations":" ","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • cisplatin • carboplatin • albumin-bound paclitaxel • KM1"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 02/01/2023","start_date":" 02/01/2023","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2023-01-13"}]